Spectrum Gets FDA Nod For Febrile Neutropenia Candidate, Sees Commercial Launch In Q4 2022

The U.S. Food and Drug Administration (FDA) has approved Spectrum Pharmaceuticals’ SPPI lead asset ROLVEDON (eflapegrastim-xnst) injection to decrease the incidence of infection, as manifested by febrile neutropenia.

ROLVEDON (eflapegrastim-xnst) injection is a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation

The company has received an indication to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.

The regulatory submission was supported by data from ADVANCE and RECOVER, two Phase 3 clinical trials which evaluated the safety and efficacy of ROLVEDON in 643 early-stage breast cancer patients for the management of neutropenia due to myelosuppressive chemotherapy.

In both studies, ROLVEDON demonstrated the pre-specified hypothesis of non-inferiority (NI) in mean duration of severe neutropenia (DSN) and a similar safety profile to pegfilgrastim.

Tom Riga, President and Chief Executive Officer, commented: "ROLVEDON's approval marks Spectrum's transformation to a commercial-stage company with the opportunity to compete in a $2 billion dollar market, and offers a unique value proposition. This approval is a significant milestone for our development team and collaboration with Hanmi Pharmaceutical.”

The company expects to launch with product available in the fourth quarter of 2022.

Price Target : Spectrum shares are trading around 12 percent higher at $1.45 on Friday during after-hours session.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMovers & ShakersFDAGeneralFDA Approval
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!